# PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

Source: https://onco.cc/trials/nct07510828/  
OnCo record `nct07510828` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of EB-PT-CAR-NK-S in advanced solid tumours, run by Beijing Biotech, now recruiting.

## Summary

PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07510828 by Beijing Biotech, with 60 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-PT-CAR-NK-S, EB-PT-CAR-NK-D, Lymphodepleting chemotherapy and Cytokine support.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07510828
- Phase: 1/2
- Setting: A Phase 1/2 Biomarker-Guided Platform Study of Allogeneic Donor-Derived Single-Target or Dual-Target CAR-NK Cell Therapy Selected by Tumor Antigen Profiling (Liquid Biopsy and/or Tissue Biopsy) in Participants With Advanced Solid Tumors
- Sponsor: Beijing Biotech
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07510828: https://clinicaltrials.gov/study/NCT07510828

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07510828.json